louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03742934: Short Peptide Formula for Bowel Preparation
Official title: Evaluation of Short Peptide Formula for Bowel Preparation in Video Capsule Endoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Capsule Endoscopy
Pediatric Disorder
Keywords: Bowel preparation
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2018-11-15
Enrollment: 210
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Video capsule endoscopy (VCE) is a noninvasive diagnostic tool used to assess the small bowel pathology. The diagnostic value of VCE is mostly dependent on the cleanliness of the colon. Investigators are aimed to prospectively assess the quality of bowel preparation in pediatric patients receiving short peptide diet versus those receiving liquid diet.


Eligibility criteria: Inclusion Criteria:

* Indications of capsule endoscopy;
* Informed consent form obtained.

Exclusion Criteria:

* Contraindication of capsule endoscopy;
* Unwilling to participate;
* Formula allergy;
* Unable to swallow the capsule.

Primary outcomes:
measure: Cleansing score
timeFrame: assessed through study completion, an average of 1 year
Secondary outcomes:
measure: Diagnostic yield
timeFrame: assessed through study completion, an average of 1 year
measure: Completion rate
timeFrame: assessed through study completion, an average of 1 year
Other outcomes:
measure: Adverse events
timeFrame: assessed through study completion, an average of 1 year
measure: Bristol scores
timeFrame: assessed through study completion, an average of 1 year
Locations:
city: Shanghai
country: China
facility: Children's hospital of Fudan university
state: Shanghai
Study officials:
affiliation: Children's Hospital of Fudan University
name: Ying Huang, PhD
role: STUDY_DIRECTOR
References:
citation: Goyal J, Goel A, McGwin G, Weber F. Analysis of a grading system to assess the quality of small-bowel preparation for capsule endoscopy: in search of the Holy Grail. Endosc Int Open. 2014 Sep;2(3):E183-6. doi: 10.1055/s-0034-1377521. Epub 2014 Jul 16.
citation: van Tuyl SA, den Ouden H, Stolk MF, Kuipers EJ. Optimal preparation for video capsule endoscopy: a prospective, randomized, single-blind study. Endoscopy. 2007 Dec;39(12):1037-40. doi: 10.1055/s-2007-966988.
Clinical trial NCT03276234: Is There a Relationship Between Serum Sodium Level and Mean Platelet Volume (MPV) Value
Official title: Is There a Relationship Between Serum Sodium Level and Mean Platelet Volume (MPV) Value in Patients Undergoing Transurethral Prostate Resection (TUR)?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mean Platelet Volume According to Serum Sodium Value
on Patients Who Will Have Transurethral Resection of the Prostate
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2017-09-08
Enrollment: 31
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Male patients who will be done TUR.

Brief summary: Is there a relationship between serum sodium level and mean platelet volume (MPV) value in patients undergoing transurethral prostate resection (TUR)?

Detailed description: Thirty one patients undergoing transurethral prostate resection (TUR)? will be evaluated.The relationship between serum sodium value and MPV value of patients will be evaluated.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologist (ASA) physical status 1 and 3
* Patients between the ages of 18 and 80

Exclusion Criteria:

* Patients with bleeding disorder
* Patients with blood transfusion
* Patients are that sodium values are lower than normal range.

Primary outcomes:
measure: Mean platelet volume
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Male patients between 18 and 80 years of age who have undergone TUR.
Study officials:
References:
Clinical trial NCT04292834: A Registered Cohort Study of Immune-Mediated Neuropathies
Official title: A Registered Cohort Study of Immune-Mediated Neuropathies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
Collaborators: name: Beijing Tiantan Hospital
First posted: 2020-03-03
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with GBS,CIDP,MMN who are diagnosied in the First Affiliated Hospital of Fujian Medical Universtiy and Beijing Tiantan Hospital, Capital Medical University by two neurolgists

Brief summary: This study will provide further insights into the natural course of the disease about Immune-Mediated Neuropathies including clinical features，progression, related antibody spectrum and drug treatment effect.


Eligibility criteria: Inclusion Criteria:

- 1. Outpatient or inpatient 2. Meet the diagnostic criteria of various inflammatory peripheral neuropathy. 3. Voluntary participation and informed consent signed by the applicant or his/her family.

4. Age 18 or above

Exclusion Criteria:

1. Severe complications
2. Poor prognosis (\<1 year survival)
3. Severe mental disorder and inability to cooperate with the examination.
4. Age less than 18

Primary outcomes:
measure: The correlation between clinical phenotypes and Serum antibodies
timeFrame: from date of enrollment until the date of death from any cause,assessed up to 20 years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital, Capital Medical University
state: Beijing
city: Fuzhou
country: China
facility: Department of Neurology,First Affiliated Hospital of Fujian Medical University
state: Fujian
Study officials:
References:
Clinical trial NCT05035134: Application of Circulating Exosomes in Early Diagnosis and Prognosis Evaluation After Intracerebral Hemorrhage
Official title: Application of Circulating Exosomes in Early Diagnosis and Prognosis Evaluation After Intracerebral Hemorrhage
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intracerebral Hemorrhage；Circulating Exosomes
Lead sponsor: Tang-Du Hospital
Sponsor class: OTHER
First posted: 2021-09-05
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All of the ICH patients receiving treatment in Tangdu Hospital during 2021-2022

Brief summary: The purpose of this study is to observe the relationship between the changes of circulating exosomes and the development and outcome of the disease in patients with intracerebral hemorrhage, and to search for early serum markers and potential intervention targets for disease monitoring in patients with intracerebral hemorrhage


Eligibility criteria: Inclusion Criteria:

1. No systematic treatment was given before admission;
2. The patients were diagnosed with cerebral hemorrhage, and had imaging evidence;
3. The age was more than 18 years old;
4. The patient or family member agrees to sign the informed consent.

Exclusion Criteria:

1. Hematoma is caused by secondary factors (intracranial tumor, arteriovenous malformation or aneurysm);
2. Bleeding into the ventricle;
3. Multiple cerebral hemorrhage;
4. The patient did not receive treatment in our hospital;
5. Severe disability, dementia, or organ dysfunction before onset
6. Coagulopathy or long-term use of anticoagulants
7. Hematoma affects brain stem
8. Subjects refused to participate

Primary outcomes:
measure: The type and content of circulating exosomes
timeFrame: within 24 hours of ICH
measure: Modified Rankin scale (mRS) scores
timeFrame: from onset to three months or six months
Secondary outcomes:
measure: mortality
timeFrame: through study completion，an average of 1 year
measure: hospital stay
timeFrame: From hospitalization to discharge，up to one month
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Tandu Hospital, Fourth Military Medical University
Study officials:
affiliation: Tang-Du Hospital
name: Yan Qu, M.D, Ph.D
role: STUDY_CHAIR
affiliation: Tang-Du Hospital
name: Xun Wu, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00875134: Testing of the Apnea Prevention Device
Official title: Testing of the Apnea Prevention Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Respiratory Depression
Elective Surgery
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2009-04-03
Enrollment: 30
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study is designed to test the ability of a computer-based algorithm to detect and intervene in cases of narcotic-induced respiratory depression.


Eligibility criteria: Inclusion Criteria:

* Elective surgical patients

Exclusion Criteria:

* Refusal to consent to study

Primary outcomes:
measure: Efficacy in treating respiratory depression
timeFrame: seconds after desaturation
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health and Science University
state: Oregon
Study officials:
References:
Clinical trial NCT06261034: A Study of Sex Differences in Neurocirculatory Control
Official title: Sex Differences in Neurocirculatory Control With Obstructive Sleep Apnea
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obstructive Sleep Apnea
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted: 2024-02-15
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with or without untreated obstructive sleep apnea will be recruited from Mayo Clinic in Rochester, MN.

Brief summary: The purpose of this study is to investigate potential sex differences in neurocirculatory control of blood pressure in patients with untreated obstructive sleep apnea (OSA).


Eligibility criteria: Inclusion Criteria:

* 20-70 years of age

Exclusion Criteria:

* Coronary artery disease
* Heart failure
* Pregnancy
* COPD
* Diabetes
* CKD
* Sleep disorders other than OSA
* Shift workers
* Individuals who typically go to sleep after midnight
* Individuals who traveled across ≥2 time zones within one week of study visits
* BMI ≥40.0kg/m2
* Use of nicotine-containing products within the two years preceding study visits
* Use of allopurinol, proton pump inhibitors, or other medications/supplements which interfere with outcome measures

Primary outcomes:
measure: Blood pressure
timeFrame: Baseline
measure: Arterial stiffness
timeFrame: Baseline
measure: Endothelial function
timeFrame: Baseline
Secondary outcomes:
measure: Sympathetic nerve burst frequency
timeFrame: Baseline
measure: Sympathetic nerve burst incidence
timeFrame: Baseline
measure: Sympathetic nerve burst amplitude (AU)
timeFrame: Baseline
measure: Total muscle sympathetic nerve activity (MSNA)
timeFrame: Baseline
Other outcomes:
measure: Cerebral autoregulation
timeFrame: Baseline
measure: Sympathetic action potentials per burst
timeFrame: Baseline
measure: Sympathetic action potential clusters per burst
timeFrame: Baseline
measure: Sympathetic action potential conduction latency of each cluster
timeFrame: Baseline
measure: Immune function
timeFrame: Baseline
measure: Urinary Extracellular Vesicle Presence and Content
timeFrame: Baseline
measure: Plasma Extracellular Vesicle Presence and Content
timeFrame: Baseline
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Joshua Bock, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03659734: Motivational Interviewing and Guided Opioid Tapering Support to Promote Postoperative Opioid Cessation
Official title: Randomized Controlled Trial to Evaluate the Relative Efficacy of Motivational Interviewing and Guided Opioid Tapering Support vs. Enhanced Usual Care to Promote Opioid Cessation After Orthopedic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid Cessation
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2018-09-06
Enrollment: 179
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the relative efficacy of enhanced usual care versus motivational interviewing and guided opioid tapering support to promote opioid cessation after total hip or knee replacement surgery.


Eligibility criteria: Inclusion Criteria:

* Planning to undergo surgery
* English speaking
* Ability and willingness to complete questionnaires and assessments
* Scheduled for total hip, knee, or shoulder replacement
* Preoperative opioid use and opioid use 14 days after surgery to increase the likelihood of delayed opioid cessation.
* Not under the care of a current pain management provider

Exclusion Criteria:

* Any conditions causing inability to complete assessments
* Known pregnancy
* Elevated suicidality
* Enrollment in conflicting perioperative trial

Primary outcomes:
measure: Time to Opioid Cessation
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Number of Participants With Opioid Misuse (Postoperative COMM Score Greater Than or Equal to 9)
timeFrame: Through study completion, 1 year after surgery
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Jennifer Hah, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01331434: Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions
Official title: A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fed Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2011-04-08
Enrollment: 47
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fed conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to exemestane or any comparable or similar product.

Primary outcomes:
measure: bioequivalence determined by statistical comparison Cmax
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Springfield
country: United States
facility: Bio-Kinetic Clinical Applications, Inc.
state: Missouri
Study officials:
affiliation: Bio-Kinetic Clinical Applications, Inc.
name: Dennis N Morrison, D.O.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05252234: Post SARS-Cov-2 Disease Anesthesia Events
Official title: Post SARS-Cov-2 Disease Anesthesia Events
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intraoperative Hypertension
Pain Threshold
Postoperative Pain
Postoperative Hypoxemia
Keywords: SARS-Cov-2
Anesthesia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-02-23
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Above 18 years undergoing surgery with past history of covid-19

Brief summary: Estimating and recording the rate of occurrence of pulmonary and cardiovascular complications during the perioperative period in patients with past covid infection


Eligibility criteria: Inclusion Criteria:

* all patients above 18 years with past history of covid-19 during past 6 months undergoing surgery

Exclusion Criteria:

* hemodynamically unstable Patients requiring oxygen therapy

Primary outcomes:
measure: Rate of occurrence of pulmonary and cardiovascular complications
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of medicine, Ain Shams University
Study officials:
affiliation: Ain Shams University
name: Fathy Tash, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03689634: Move For Surgery - A Novel Preconditioning Program
Official title: Move For Surgery - A Novel Preconditioning Program to Optimize Health Before Thoracic Surgery: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Lung Cancer, Nonsmall Cell
Lead sponsor: St. Joseph's Healthcare Hamilton
Sponsor class: OTHER
Collaborators: name: Hamilton Academic Health Sciences Organization
First posted: 2018-09-28
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Lung cancer is the leading cause of cancer death in Canada. Most patients with this cancer will undergo treatment with major chest surgery that is associated with serious complications. As many as 50% of patients will suffer respiratory complications after surgery, keeping them in the hospital for extended periods of time. These long hospitalizations have a dramatic negative effect on the lives of those people, in addition to a large cost burden on our healthcare system. Traditionally, patients who suffer from complications are treated with rehabilitation AFTER the complications have occurred. But what if complications can be prevented BEFORE they happen? Having major chest surgery imposes great stress on the human body, one that is equivalent to running a marathon. Analogous to training before completing a marathon, the investigator designed Move For Surgery (MFS), a novel preconditioning program that encourages and empowers patients to improve their health prior to surgery. The investigator aims to demonstrate that patients who train with Move For Surgery will have lower respiratory complication rates, will recover better, and will leave the hospital sooner than their counterparts.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Clinical stage I, II, or IIIa non-small cell lung cancer (NSCLC)
* Candidates for thoracic surgery, as determined by the operating surgeon

Exclusion Criteria:

* Clinical stage IIIb or IV NSCLC
* Patients with affected mobility (wheelchair, walker)
* Patients who use oxygen at home

Primary outcomes:
measure: The primary outcome of the comparative trial will be length of stay (LOS) in hospital after surgery, which will also be used to measure speed of recovery from surgery and postoperative complications.
timeFrame: 24 months
Secondary outcomes:
measure: Secondary outcome will include differences in the 36-Item Short Form Health Survey (SF-36) scores before and after the intervention.
timeFrame: 24 months
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: St. Joseph's Healthcare Hamilton
state: Ontario
Study officials:
References:
Clinical trial NCT00791934: Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide
Official title: Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide (Kenalog-40)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sinusitis
Lead sponsor: Integra LifeSciences Corporation
Sponsor class: INDUSTRY
Collaborators: name: Acclarent
First posted: 2008-11-17
Enrollment: 63
Sex: ALL
Minimum age (years): 17
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study Design:

A non-randomized, multi-center, prospective, clinical study intended to evaluate the safety and efficacy of treating the ethmoid sinuses with the Ethmoid Sinus Spacer and Access System used for the local delivery of Triamcinolone Acetonide, over a period of 28 days.


Eligibility criteria: Inclusion Criteria:

* Male or female subjects age 17 years or older
* Radiographic evidence of ethmoid disease (baseline CT scan obtained within 30 days of scheduled surgery)
* Diagnosis of chronic sinusitis and failed medical management (minimum of 3 weeks of antibiotics)

Exclusion Criteria:

* Age \< 17 years old
* History of glaucoma or diagnosis of glaucoma (baseline visual exam indicating IOP \>21 mmHg)
* Adequate anatomical distances for treatment
* Patient received oral steroid treatment within two weeks prior to day of surgery
* Radiographic evidence of extensive sinonasal osteoneogenesis which could prevent device placement
* Sinonasal tumors or obstructive lesions
* History of facial trauma that distorts sinus anatomy and precludes access to the ethmoid sinus
* Contracted/underdeveloped ethmoid sinus
* Dehiscent lamina orbitalis
* Previous ethmoid surgery
* Ethmoid mucocele
* Extensive Nasal Polyps
* Asthmatic patients with aspirin sensitivity
* Pregnant or lactating females

Primary outcomes:
measure: Mean Intrapatient Change in Ethmoid Lund-MacKay CT Score (Ethmoid Score Only) at 10 Weeks Post-procedure Compared to Baseline.
timeFrame: 10 weeks post-procedure
Secondary outcomes:
measure: Number of Participants With Decrease in Vision Greater Than 2 Lines Per Snellen Chart (BCVA at Baseline vs. BCVA 10 Week Post-procedure)
timeFrame: 10 weeks post surgery
measure: Number of Participants With Either a Change in Intraocular Pressure (IOP) ≥10mmHg OR Documented IOP > 21 mmHg
timeFrame: 10 weeks post-procedure
measure: Mean Intra-patient Change in SNOT-20 Score Post-procedure Compared to Baseline
timeFrame: 1 year
measure: Mean Intra-patient Change in SNOT-20 Score Post-procedure Compared to Baseline
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Lahey Clinic
state: Massachusetts
Study officials:
affiliation: Lahey Clinic
name: Peter Catalano, MD
role: PRINCIPAL_INVESTIGATOR
References: